Aminoglycoside Administration in Septic Patients
Sepsis is one of the main causes of mortality and morbidity in an ICU setting, while the responsible microorganisms most frequently isolated are multidrug-resistant gram-negative bacteria. Aminoglycoseides (AG) seem to be particularly effective in dealing with these microbes, however their potential toxicity, especiall
| Condition(s) | Sepsis, Septic Shock, Aminoglycoside Toxicity, Renal Replacement Therapy |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | Sepsis is one of the main causes of mortality and morbidity in an ICU setting, while the responsible microorganisms most frequently isolated are multidrug-resistant gram-negative bacteria. Aminoglycoseides (AG) seem to be particularly effective in dealing with these microbes, however their potential toxicity, especially nephrotoxicity, often makes them an unsuitable treatment option. This becomes particularly evident in patients with already impaired renal function, a common occurrence in septic patients requiring ICU treatment. AG are bacteriocidal antibiotics the efficiency of which depends on the maximum concentration in patients' serum (Cpeak). Pathophysiological changes in critically ill patients, result in significant distribution of the drug extravascullary resulting in a decreased |
| Who can participate | Inclusion Criteria: * age \>18 years * diagnosis of sepsis or septic shock based on established criteria (Sepsis-3) 29 * patients with GFR \<40 ml/min * microbiemia from a Gram-negative microorganism and for which the attending physician decides to receive an aminoglycoside or sepsis/septic shock for which it is decided to administer it * signed consent of the patients' next of kin Exclusion Criteria: * absence of consent * known allergic reaction to aminoglycosides * infection from strains resistant to aminoglycosides. As long as the patient has received an aminoglycoside (empirical regimen) and the antibiogram follows it, the treatment can be modified based on the judgment of the attending physician, but the patient's data for the time he received the treatment under consideration are re |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | University of Thessaly |
| Locations | Larissa, Thessaly, Greece |
| Start date | 2023-06-02 |
| NCT ID | NCT06226441 |
| Official listing | https://clinicaltrials.gov/study/NCT06226441 |